These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4138250)

  • 41. [Graves-Basedow type ophthalmopathy and primary hypothyroidism].
    Cathelineau G; Fribourg-Desi M
    Nouv Presse Med; 1974 Sep; 3(32):1995-8. PubMed ID: 4372586
    [No Abstract]   [Full Text] [Related]  

  • 42. The thyroid-stimulating antibody of Graves' disease: evidence for restricted heterogeneity.
    Zakarija M
    Horm Res; 1980; 13(1):1-15. PubMed ID: 6777285
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [L.A.T.S. activity during hyperthyroidism. Apropos of 143 cases of Basedow's disease].
    Letonturier P; Tourneur R; Sénécal P
    Ann Med Interne (Paris); 1974 May; 125(5):463-7. PubMed ID: 4140703
    [No Abstract]   [Full Text] [Related]  

  • 44. Proceedings: Studies on long-acting thyroid stimulator protector in serum containing long-acting thyroid stimulator.
    Dirmikis S; Munro DS
    J Endocrinol; 1975 Mar; 64(3):29P-30P. PubMed ID: 1173370
    [No Abstract]   [Full Text] [Related]  

  • 45. Aetiology of hyperthyroidism. II.
    Hoffenberg R
    Br Med J; 1974 Aug; 3(5929):508-10. PubMed ID: 4369764
    [No Abstract]   [Full Text] [Related]  

  • 46. [Hyperthyroidism and the "long acting thyroid stimulator" (LATS)].
    Studer H
    Schweiz Med Wochenschr; 1967 May; 97(19):622-3. PubMed ID: 5632362
    [No Abstract]   [Full Text] [Related]  

  • 47. Adenylate cyclase activity in thyroid tissue from patients with untreated Graves' disease.
    Kasagi K; Konishi J; Endo K; Mori T; Nagahara K; Makimoto K; Kuma K; Torizuka K
    J Clin Endocrinol Metab; 1980 Sep; 51(3):492-9. PubMed ID: 6893334
    [No Abstract]   [Full Text] [Related]  

  • 48. The pathogenesis of Graves' disease. A disorder of delayed hypersensitivity?
    Volpe R; Edmonds M; Lamki L; Clarke PV; Row VV
    Mayo Clin Proc; 1972 Nov; 47(11):824-34. PubMed ID: 4678500
    [No Abstract]   [Full Text] [Related]  

  • 49. Neutralization of the long-acting thyroid stimulator by thyroid subcellular fractions.
    Berumen FO; Lobsenz IL; Utiger RD
    J Lab Clin Med; 1967 Oct; 70(4):640-9. PubMed ID: 6072404
    [No Abstract]   [Full Text] [Related]  

  • 50. The long-acting thyroid stimulator of Graves' disease.
    Burke G
    Am J Med; 1968 Sep; 45(3):435-50. PubMed ID: 4876801
    [No Abstract]   [Full Text] [Related]  

  • 51. Validation of cytochemical section bioassay for thyroid-stimulating immunoglobulins in treated and untreated Graves' disease.
    Prentice MG; Alaghband-Zadeh J; Wise PH
    J Immunoassay; 1984; 5(3-4):275-90. PubMed ID: 6549396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Correlation of long-acting thyroid stimulator with serum levels of tri-iodothyronine, thyroxine and thyrotropin in Graves' disease.
    Sawhney RC; Kannan V; Rastogi GK
    J Assoc Physicians India; 1975 Feb; 23(2):111-4. PubMed ID: 1242389
    [No Abstract]   [Full Text] [Related]  

  • 53. Investigation of endocrine exophthalmos.
    Bowden AN; Ross FC
    Proc R Soc Med; 1969 Jan; 62(1):13-5. PubMed ID: 5818230
    [No Abstract]   [Full Text] [Related]  

  • 54. [LATS and Graves' disease].
    Gordon A
    Harefuah; 1971 May; 80(10):569-70. PubMed ID: 5171988
    [No Abstract]   [Full Text] [Related]  

  • 55. Indirect immunofluorescence and generation of cyclic-AMP investigation with Graves' patients' sera.
    Szabó J; Fórizs E; Szabó T; Leövey A
    Acta Med Hung; 1986; 43(3):275-81. PubMed ID: 3035480
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs.
    Mukhtar ED; Smith BR; Pyle GA; Hall R; Vice P
    Lancet; 1975 Mar; 1(7909):713-5. PubMed ID: 47482
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Graves' IgG stimulation of continuously cultured rat thyroid cells: a sensitive and potentially useful clinical assay.
    Vitti P; Valente WA; Ambesi-Impiombato FS; Fenzi GF; Pinchera A; Kohn LD
    J Endocrinol Invest; 1982; 5(3):179-82. PubMed ID: 6286749
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum long acting thyroid stimulator (LATS) and LATS-protector (LATS-P) in Graves' disease associated with localized myxedema.
    Hardisty CA; Fowles A; Munro DS
    J Endocrinol Invest; 1984 Apr; 7(2):151-5. PubMed ID: 6547156
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
    Silverstein GE; Burke G
    Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
    [No Abstract]   [Full Text] [Related]  

  • 60. A reconsideration of a thyroid-stimulating immunoglobulin as the cause of hyperthyroidism in Graves' disease.
    McKenzie JM; Zakarija M
    J Clin Endocrinol Metab; 1976 Apr; 42(4):778-81. PubMed ID: 177449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.